[Homozygous Sickle Cell Children Treated with Hydroxyurea in Brazzaville (Congo)]. / Le devenir des enfants atteints de drépanocytose homozygote traités par hydroxyurée à Brazzaville (Congo).

The objective of this study is to reduce the morbidity of children with homozygous sickle cell disease presenting severe forms. We have conducted a longitudinal study between November 2015 and September 2017 at the Brazzaville University Hospital. Children with sickle cell disease requiring treatment with hydroxyurea were included. The variables studied were therapeutic compliance, evolutive profile of nutritional status, indications of hydroxyurea, electrophoresis of hemoglobin, blood count, and toxicity. The statistical test used was Student test with a significance threshold of less than 0.05. One thousand twenty-four children were monitored for sickle cell disease, 107 of which had received hydroxyurea (10.4%). The indications for hydroxyurea were recurrent anemic attacks (≥ 4) in 62 cases (57.9%), neurological crises 19 cases (17.8%), recurrent hyperalgesic crises in 17 cases (15.9%), priapism in 4 cases (3.7), and acute thoracic syndrome in 2 cases (1.9%). Therapeutic compliance was good in 89.5% of them. A rapid and lasting clinical improvement was noted in the majority of patients with hyperalgesic attacks (88.2%) and anemic attacks (88.7%), two recurrences for the cerebrovascular accidents, and an absence of recurrence of priapism and of the acute thoracic syndrome. From the biological point of view, there was a significant increase in fetal hemoglobin (1.2 to 16.2%; P  < 0.05), hemoglobin (7 to 8.3 g/dl; P < 0.05), mean cell volume (80.8 to 96 fl; P  < 0.05) and a significant decrease in mean white blood cell count (15,633 to 9,872/mm3; P  < 0.05) and platelets (387,002 to 324,400/mm3; P  < 0.05). The signs of toxicity observed were mainly vomiting and thrombocytopenia in two cases each, one case with headache and the other with neutropenia. Indications for use of hydroxyurea therapy in children with sickle cell disease in Brazzaville are common. These are dominated by recurrent anemic seizures, strokes, and hyperalgesic seizures. The excellent evolution of these complications under hydroxyurea represents an interesting alternative in our countries with limited resources.

Il s'agit d'une étude longitudinale réalisée entre novembre 2015 et septembre 2017 au CHU de Brazzaville. L'étude a porté sur une série hospitalière d'enfants atteints de drépanocytose homozygote et présentant des complications sévères qui imposaient le recours à l'hydroxyurée. Les variables étudiées étaient l'observance thérapeutique, l'évolution de l'état nutritionnel, des indications de l'hydroxyurée, des éléments de l'hémogramme et de l'électrophorèse de l'hémoglobine au cours du traitement, les effets secondaires et les signes de toxicité. La comparaison des moyennes des éléments hématologiques avant le traitement et la fin de l'étude a fait appel au test t de Student, avec un seuil de significativité fixé à 0,05. Sur 1 024 enfants suivis pour drépanocytose, 107 présentaient une indication de traitement par hydroxyurée, soit 10,4 %. Ces indications étaient des épisodes anémiques récurrents (≥ 4) dans 62 cas, des accidents neurovasculaires dans 19 cas, des hyperalgies récurrentes dans 17 cas, un priapisme permanent dans quatre cas et un syndrome thoracique aigu dans deux cas. L'observance thérapeutique était bonne pour 89,5 % des enfants traités. Une amélioration clinique rapide et durable était notée dans la majorité des enfants, avec 88,2 % pour les crises hyperalgiques, et 88,7 % pour les crises anémiques, deux cas de récidives de crise neurovasculaire, mais aucune pour le priapisme et le syndrome thoracique aigu. Sur le plan biologique, on a constaté une augmentation significative du taux de l'hémoglobine fœtale (1,2 à 16,2 % ; p < 0,05), de l'hémoglobine (7 à 8,3 g/dl ; p < 0,05), du volume globulaire moyen (80,8 à 96 fl ; p < 0,05), et une baisse significative du nombre de globules blancs (15 633 à 9 872/mm3 ; p < 0,05) et des plaquettes (387 002 à 324 400/mm3 ; p < 0,05). Les effets secondaires observés étaient essentiellement des vomissements et une thrombopénie dans deux cas chacun, ainsi qu'un cas de céphalée et une neutropénie. Les indications de traitement par hydroxyurée chez l'enfant atteint de drépanocytose à Brazzaville sont nombreuses. Celles-ci sont dominées par les épisodes anémiques récurrents, les accidents vasculaires cérébraux et les crises hyperalgiques. L'excellente évolution de ces complications sous hydroxyurée représente une alternative intéressante dans nos pays à ressources limitées.

Outcome of HIV-positive children and adolescents treated with second-line antiretroviral agents in Congo.

Antiretroviral agents (ARVs) are the leading therapeutic weapon against HIV/AIDS infection. When first-line treatment fails, a second-line ARV is needed. OBJECTIVE: To determine the prevalence of HIV-infected children treated with second-line ARVs, to assess their adherence and therapeutic response, and to identify factors of good adherence. MATERIAL AND METHODS: A retrospective multicenter study covering the period from January 2015 to July 2016 in all centers providing care to children with HIV included all children treated with a second-line ARV. RESULTS: A total of 71 children were identified, with a male to female ratio of 1.1 and a mean age of 14.2±3.2 years (range: 5 to 19). Mother-to-child transmission was observed for 97.2 %. In all, 64.8 % of the children had lost at least one parent, 29.6 % both of them. Family socioeconomic status was low for 15.5 % and middle for 74.6 %. Nearly half (46.5 %) were aware of their HIV status, and all received psychological support. The therapeutic regimen used for 54.9 % included ABC + DDI + LPV/r, and the treatment lasted for less than 2 years in 22.5 % and between 2 and 4 years in 38 %. Therapeutic adherence was good in 54.9 %, better in boys (p < 0.01) and in those aged 15 years and younger (p < 0.001). The therapeutic response was good in 89 % at 12 months and 86 % at 4 years, better in those aged 15 years and younger (p < 0.001). CONCLUSION: Despite the small proportion of good therapeutic adherence to second-line ARVs, the rate of good clinical and therapeutic response of 86 % in children and adolescents 4 years after being switched to them is an argument that should encourage prescribers to shift patients to second-line treatment as soon as there is an indication. However, challenges remain in improving the management of children and adolescents treated with a second-line ART.